{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T19:02:57Z","timestamp":1792522977405,"version":"4.5.0"},"reference-count":161,"publisher":"Informa UK Limited","issue":"19","funder":[{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["C6228\/5437"],"award-info":[{"award-number":["C6228\/5437"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["C6228\/5433"],"award-info":[{"award-number":["C6228\/5433"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"crossref","award":["C6228\/A12512"],"award-info":[{"award-number":["C6228\/A12512"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Worldwide Cancer Research","award":["AICR 06-034"],"award-info":[{"award-number":["AICR 06-034"]}]},{"name":"Yorkshire Cancer Research","award":["L376PA"],"award-info":[{"award-number":["L376PA"]}]},{"name":"Yorkshire Cancer Research","award":["L367"],"award-info":[{"award-number":["L367"]}]},{"name":"Yorkshire Cancer Research","award":["L346"],"award-info":[{"award-number":["L346"]}]},{"name":"Yorkshire Cancer Research","award":["L372"],"award-info":[{"award-number":["L372"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Future Oncol."],"published-print":{"date-parts":[[2016,10,31]]},"DOI":"10.2217\/fon-2016-0042","type":"journal-article","created":{"date-parts":[[2016,7,6]],"date-time":"2016-07-06T03:49:30Z","timestamp":1467776970000},"page":"2243-2263","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":54,"title":["A Place for Precision Medicine in Bladder Cancer: Targeting the Fgfrs"],"prefix":"10.1080","volume":"12","author":[{"given":"Erica","family":"di Martino","sequence":"first","affiliation":[{"name":"Section of Molecular Oncology, Leeds Institute of Cancer &amp; Pathology, St James\u2019s University Hospital, Beckett Street, Leeds, LS9 7TF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren C","family":"Tomlinson","sequence":"additional","affiliation":[{"name":"Astbury Centre for Structural &amp; Molecular Biology, School of Molecular &amp; Cellular Biology, Astbury Building, University of Leeds, Leeds, LS2 9JT, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah V","family":"Williams","sequence":"additional","affiliation":[{"name":"Section of Molecular Oncology, Leeds Institute of Cancer &amp; Pathology, St James\u2019s University Hospital, Beckett Street, Leeds, LS9 7TF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret A","family":"Knowles","sequence":"additional","affiliation":[{"name":"Section of Molecular Oncology, Leeds Institute of Cancer &amp; Pathology, St James\u2019s University Hospital, Beckett Street, Leeds, LS9 7TF, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2016,7,6]]},"reference":[{"key":"e_1_3_2_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.25516"},{"key":"e_1_3_2_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2013.06.003"},{"key":"e_1_3_2_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2005.12.031"},{"key":"e_1_3_2_5_1","doi-asserted-by":"publisher","DOI":"10.1100\/tsw.2006.404"},{"key":"e_1_3_2_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40273-014-0194-2"},{"key":"e_1_3_2_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2014.01.006"},{"key":"e_1_3_2_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.757"},{"key":"e_1_3_2_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)42494-3"},{"key":"e_1_3_2_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.32.3139"},{"key":"e_1_3_2_11_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa022148"},{"key":"e_1_3_2_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23692"},{"key":"e_1_3_2_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3817"},{"key":"e_1_3_2_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2014.11.003"},{"key":"e_1_3_2_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd2792"},{"key":"e_1_3_2_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/0014-5793(93)80882-U"},{"key":"e_1_3_2_17_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.271.25.15292"},{"key":"e_1_3_2_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0065-230X(08)60821-0"},{"key":"e_1_3_2_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)78170-8"},{"key":"e_1_3_2_20_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M300281200"},{"key":"e_1_3_2_21_1","doi-asserted-by":"publisher","DOI":"10.1091\/mbc.12.4.931"},{"key":"e_1_3_2_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/12615"},{"key":"e_1_3_2_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1771"},{"key":"e_1_3_2_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(20011115)92:10<2555::AID-CNCR1607>3.0.CO;2-M"},{"key":"e_1_3_2_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1204110"},{"key":"e_1_3_2_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199203123261104"},{"issue":"4","key":"e_1_3_2_27_1","first-page":"1265","article-title":"The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate","volume":"61","author":"Van Rhijn BW","year":"2001","unstructured":"Van Rhijn BW , LurkinI, RadvanyiF, KirkelsWJ, Van Der KwastTH, ZwarthoffEC. The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate. Cancer Res.61(4), 1265\u20131268 (2001).","journal-title":"Cancer Res."},{"key":"e_1_3_2_28_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ejhg.5200883"},{"key":"e_1_3_2_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgh275"},{"key":"e_1_3_2_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.canep.2010.05.003"},{"issue":"1","key":"e_1_3_2_31_1","first-page":"71","article-title":"Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I","volume":"9","author":"D\u2019Avis PY","year":"1998","unstructured":"D\u2019Avis PY , RobertsonSC, MeyerAN, BardwellWM, WebsterMK, DonoghueDJ. Constitutive activation of fibroblast growth factor receptor 3 by mutations responsible for the lethal skeletal dysplasia thanatophoric dysplasia type I. Cell Growth Differ.9(1), 71\u201378 (1998).","journal-title":"Cell Growth Differ."},{"key":"e_1_3_2_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2009.280"},{"key":"e_1_3_2_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpj.2014.11.3460"},{"key":"e_1_3_2_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2013.07.017"},{"key":"e_1_3_2_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)64665-2"},{"key":"e_1_3_2_36_1","volume-title":"WHO Classification Tumors of the Urinary System and Male Genital Organs","author":"WHO","year":"2004","unstructured":"WHO . WHO Classification Tumors of the Urinary System and Male Genital Organs. IARC Press, Lyon, France (2004)."},{"key":"e_1_3_2_37_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.1202"},{"key":"e_1_3_2_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1130"},{"key":"e_1_3_2_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2008.06.013"},{"key":"e_1_3_2_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.07.039"},{"key":"e_1_3_2_41_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0122"},{"key":"e_1_3_2_42_1","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgi290"},{"key":"e_1_3_2_43_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-14-0022"},{"key":"e_1_3_2_44_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/dds486"},{"key":"e_1_3_2_45_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12965"},{"key":"e_1_3_2_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2798"},{"key":"e_1_3_2_47_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0927-T"},{"key":"e_1_3_2_48_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1092586"},{"key":"e_1_3_2_49_1","doi-asserted-by":"publisher","DOI":"10.1242\/jcs.094607"},{"key":"e_1_3_2_50_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1220834"},{"key":"e_1_3_2_51_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-1718"},{"key":"e_1_3_2_52_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M601252200"},{"key":"e_1_3_2_53_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.2207"},{"key":"e_1_3_2_54_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djs444"},{"key":"e_1_3_2_55_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-014-1596-4"},{"key":"e_1_3_2_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejso.2005.11.018"},{"key":"e_1_3_2_57_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.459.11.2"},{"key":"e_1_3_2_58_1","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.262"},{"key":"e_1_3_2_59_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-09-0744"},{"issue":"2","key":"e_1_3_2_60_1","first-page":"855","article-title":"The tumorigenic FGFR3\u2013TACC3 gene fusion escapes miR-99a regulation in glioblastoma","volume":"123","author":"Parker BC","year":"2013","unstructured":"Parker BC , AnnalaMJ, CogdellDEet al. The tumorigenic FGFR3\u2013TACC3 gene fusion escapes miR-99a regulation in glioblastoma. J. Clin. Invest.123(2), 855\u2013865 (2013).","journal-title":"J. Clin. Invest."},{"key":"e_1_3_2_61_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.240"},{"key":"e_1_3_2_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2010.03.084"},{"key":"e_1_3_2_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajpath.2010.11.061"},{"key":"e_1_3_2_64_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0077-T"},{"key":"e_1_3_2_65_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030206"},{"key":"e_1_3_2_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2011.09.008"},{"issue":"0","key":"e_1_3_2_67_1","first-page":"835","article-title":"Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study","volume":"54","author":"Burger M","year":"2007","unstructured":"Burger M , Van Der AaMN, Van OersJMet al. Prediction of progression of non-muscle-invasive bladder cancer by WHO 1973 and 2004 grading and by FGFR3 mutation status: a prospective study. Eur. Urol.54(0), 835\u2013844 (2007).","journal-title":"Eur. Urol."},{"key":"e_1_3_2_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2010.05.043"},{"key":"e_1_3_2_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/path.4017"},{"key":"e_1_3_2_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cytogfr.2005.01.001"},{"key":"e_1_3_2_71_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1349-7006.2008.00840.x"},{"key":"e_1_3_2_72_1","doi-asserted-by":"publisher","DOI":"10.1126\/stke.2282004pe17"},{"key":"e_1_3_2_73_1","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.11.10.5068-5078.1991"},{"key":"e_1_3_2_74_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203650"},{"key":"e_1_3_2_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2007.08.003"},{"key":"e_1_3_2_76_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1208705"},{"key":"e_1_3_2_77_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-13-0050"},{"key":"e_1_3_2_78_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-1329"},{"key":"e_1_3_2_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2011.10.026"},{"key":"e_1_3_2_80_1","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddp116"},{"key":"e_1_3_2_81_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0086470"},{"key":"e_1_3_2_82_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-014-9497-1"},{"key":"e_1_3_2_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0960-9822(03)00086-1"},{"key":"e_1_3_2_84_1","doi-asserted-by":"publisher","DOI":"10.1002\/pmic.201400259"},{"key":"e_1_3_2_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1206798"},{"key":"e_1_3_2_86_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ydbio.2005.09.011"},{"key":"e_1_3_2_87_1","doi-asserted-by":"publisher","DOI":"10.1111\/his.12473"},{"key":"e_1_3_2_88_1","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2013.135"},{"key":"e_1_3_2_89_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2816"},{"key":"e_1_3_2_90_1","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2010.100354"},{"key":"e_1_3_2_91_1","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.12.1.82-88.1992"},{"key":"e_1_3_2_92_1","doi-asserted-by":"publisher","DOI":"10.1128\/mcb.11.9.4627-4634.1991"},{"key":"e_1_3_2_93_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0038972"},{"key":"e_1_3_2_94_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0057284"},{"key":"e_1_3_2_95_1","doi-asserted-by":"publisher","DOI":"10.1038\/jid.2009.97"},{"key":"e_1_3_2_96_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.a.31430"},{"issue":"4","key":"e_1_3_2_97_1","first-page":"1708","article-title":"Frequency of activating mutations in FGFR2 exon 7 in bladder tumors from patients with early-onset and regular-onset disease","volume":"7","author":"Spiegelberg C","year":"2014","unstructured":"Spiegelberg C , GiedlJ, GaisaNTet al. Frequency of activating mutations in FGFR2 exon 7 in bladder tumors from patients with early-onset and regular-onset disease. Int. J. Clin. Exp. Pathol.7(4), 1708\u20131713 (2014).","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"e_1_3_2_98_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1200830"},{"key":"e_1_3_2_99_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1202958"},{"key":"e_1_3_2_100_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1203186"},{"key":"e_1_3_2_101_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.3.241"},{"issue":"8","key":"e_1_3_2_102_1","first-page":"2083","article-title":"Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer","volume":"48","author":"Chodak GW","year":"1988","unstructured":"Chodak GW , HospelhornV, JudgeSM, MayforthR, KoeppenH, SasseJ. Increased levels of fibroblast growth factor-like activity in urine from patients with bladder or kidney cancer. Cancer Res.48(8), 2083\u20132088 (1988).","journal-title":"Cancer Res."},{"key":"e_1_3_2_103_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1464-410X.1995.tb07706.x"},{"key":"e_1_3_2_104_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-5347(17)35705-1"},{"key":"e_1_3_2_105_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00299719"},{"issue":"4","key":"e_1_3_2_106_1","first-page":"565","article-title":"Fibroblast growth factors and their specific binding sites in normal urothelium and transitional cell carcinoma (TCC) of the human bladder","volume":"41","author":"Palcy S","year":"1995","unstructured":"Palcy S , ChopinDK, CaruelleD, RaveryV, BarritaultD, CaruelleJP. Fibroblast growth factors and their specific binding sites in normal urothelium and transitional cell carcinoma (TCC) of the human bladder. Cell. Mol. Biol.41(4), 565\u2013575 (1995).","journal-title":"Cell. Mol. Biol."},{"key":"e_1_3_2_107_1","doi-asserted-by":"publisher","DOI":"10.3892\/or.2012.1948"},{"key":"e_1_3_2_108_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00428-014-1672-9"},{"key":"e_1_3_2_109_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6606016"},{"key":"e_1_3_2_110_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-0282"},{"key":"e_1_3_2_111_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0394"},{"key":"e_1_3_2_112_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI38017"},{"key":"e_1_3_2_113_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-589"},{"key":"e_1_3_2_114_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210399"},{"issue":"3","key":"e_1_3_2_115_1","doi-asserted-by":"crossref","DOI":"10.1124\/jpet.109.162768","article-title":"1-tert-butyl-3\u2013[6\u2013(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of FGFR3, inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27\/Kip1 and G1\/G0 arrest","volume":"332","author":"Miyake M","year":"2009","unstructured":"Miyake M , IshiiM, KoyamaNet al. 1-tert-butyl-3\u2013[6\u2013(3,5-dimethoxy-phenyl)-2-(4-diethylamino-butylamino)-pyrido[2,3-d]pyrimidin-7-yl]-urea (PD173074), a selective tyrosine kinase inhibitor of FGFR3, inhibits cell proliferation of bladder cancer carrying the FGFR3 gene mutation along with up-regulation of p27\/Kip1 and G1\/G0 arrest. J. Pharmacol. Exp. Ther.332(3), (2009).","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_3_2_116_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0450"},{"key":"e_1_3_2_117_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0210"},{"key":"e_1_3_2_118_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-11-0306"},{"key":"e_1_3_2_119_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-14-0248"},{"key":"e_1_3_2_120_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-12-1150"},{"key":"e_1_3_2_121_1","article-title":"Dysregulated FGF signalling in neoplastic disorders","author":"Tanner Y","year":"2015","unstructured":"Tanner Y , GroseRP. Dysregulated FGF signalling in neoplastic disorders. Semin. Cell Dev. Biol.Epub Oct 19 (2015).","journal-title":"Semin. Cell Dev. Biol."},{"key":"e_1_3_2_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drudis.2013.07.021"},{"key":"e_1_3_2_123_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2329"},{"key":"e_1_3_2_124_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2014.10.013"},{"key":"e_1_3_2_125_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-07-0193"},{"key":"e_1_3_2_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2009.09.028"},{"key":"e_1_3_2_127_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-10-2700"},{"key":"e_1_3_2_128_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2011.29.15_suppl.3079"},{"key":"e_1_3_2_129_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-07-6307"},{"key":"e_1_3_2_130_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0694"},{"key":"e_1_3_2_131_1","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2012.154"},{"key":"e_1_3_2_132_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-10-2638"},{"issue":"19","key":"e_1_3_2_133_1","article-title":"Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors","volume":"74","author":"Sequist LV","year":"2014","unstructured":"Sequist LV , CassierP, VargaAet al. Phase I study of BGJ398, a selective pan-FGFR inhibitor in genetically preselected advanced solid tumors. Cancer Res.74(19 Suppl.), Abstract CT326 (2014).","journal-title":"Cancer Res."},{"key":"e_1_3_2_134_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-11-3034"},{"key":"e_1_3_2_135_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-015-0221-6"},{"key":"e_1_3_2_136_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.7341"},{"issue":"19","key":"e_1_3_2_137_1","article-title":"JNJ-42756493 is an inhibitor of FGFR-1, 2, 3 and 4 with nanomolar affinity for targeted therapy","volume":"74","author":"Perera T","year":"2014","unstructured":"Perera T , JovchevaE, VialardJet al. JNJ-42756493 is an inhibitor of FGFR-1, 2, 3 and 4 with nanomolar affinity for targeted therapy. Cancer Res.74(Suppl. 19), Abstract 1738 (2014).","journal-title":"Cancer Res."},{"issue":"6","key":"e_1_3_2_138_1","article-title":"Identification & Biological Characterization of a Highly Potent, Irreversible Inhibitor of FGFR, TAS-2985","volume":"48","author":"Sootome H","year":"2012","unstructured":"Sootome H , FujitaH, OchiwaHet al. Identification & Biological Characterization of a Highly Potent, Irreversible Inhibitor of FGFR, TAS-2985. Eur. J. Cancer48(Suppl. 6), (2012).","journal-title":"Eur. J. Cancer"},{"key":"e_1_3_2_139_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0959-8049(12)72418-8"},{"issue":"19","key":"e_1_3_2_140_1","article-title":"FP-1039\/GSK3052230, an FGF ligand trap, enhances VEGF antagonist therapy in preclinical models of RCC and HCC","volume":"74","author":"Bellovin DI","year":"2011","unstructured":"Bellovin DI , PalenciaS, HestirKet al. FP-1039\/GSK3052230, an FGF ligand trap, enhances VEGF antagonist therapy in preclinical models of RCC and HCC. Cancer Res.74(Suppl. 19), Abstract 5449 (2011).","journal-title":"Cancer Res."},{"key":"e_1_3_2_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70294-2"},{"key":"e_1_3_2_142_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2015.02.023"},{"issue":"5","key":"e_1_3_2_143_1","article-title":"Exploratory biomarker analysis of a Phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors","volume":"32","author":"Kilgour E","year":"2014","unstructured":"Kilgour E , FerryD, SaggeseMet al. Exploratory biomarker analysis of a Phase I study of AZD4547, an inhibitor of fibroblast growth factor receptor (FGFR), in patients with advanced solid tumors. J. Clin. Oncol.32(5 Suppl.), Abstract 11010 (2014).","journal-title":"J. Clin. Oncol."},{"issue":"11","key":"e_1_3_2_144_1","article-title":"TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities","volume":"12","author":"Ochiiwa H","year":"2013","unstructured":"Ochiiwa H , FujitaH, ItohKet al. TAS-120, a highly potent and selective irreversible FGFR inhibitor, is effective in tumors harboring various FGFR gene abnormalities. Mol. Cancer Ther.12(11 Suppl.), Abstract A270 (2013).","journal-title":"Mol. Cancer Ther."},{"key":"e_1_3_2_145_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3005414"},{"key":"e_1_3_2_146_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-013-0050-x"},{"key":"e_1_3_2_147_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M110.206151"},{"key":"e_1_3_2_148_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-14-0004"},{"key":"e_1_3_2_149_1","doi-asserted-by":"publisher","DOI":"10.3892\/or.2014.3132"},{"key":"e_1_3_2_150_1","doi-asserted-by":"publisher","DOI":"10.1093\/cvr\/cvm086"},{"key":"e_1_3_2_151_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1045"},{"key":"e_1_3_2_152_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng1975"},{"key":"e_1_3_2_153_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-11-0184"},{"key":"e_1_3_2_154_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.juro.2014.06.026"},{"key":"e_1_3_2_155_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3974"},{"key":"e_1_3_2_156_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3599"},{"key":"e_1_3_2_157_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature11249"},{"key":"e_1_3_2_158_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0237"},{"key":"e_1_3_2_159_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0569"},{"key":"e_1_3_2_160_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2012.319"},{"key":"e_1_3_2_161_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2015.02.009"},{"key":"e_1_3_2_162_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2014.161"}],"container-title":["Future Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.2217\/fon-2016-0042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,23]],"date-time":"2024-06-23T02:43:33Z","timestamp":1719110613000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.2217\/fon-2016-0042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,7,6]]},"references-count":161,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2016,10,31]]}},"alternative-id":["10.2217\/fon-2016-0042"],"URL":"https:\/\/doi.org\/10.2217\/fon-2016-0042","relation":{},"ISSN":["1479-6694","1744-8301"],"issn-type":[{"value":"1479-6694","type":"print"},{"value":"1744-8301","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,7,6]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ifon20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2016-01-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-06-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-07-06","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}